Loading...
XLON
CTEC
Market cap6.25bUSD
Dec 05, Last price  
229.20GBP
1D
0.88%
1Q
-4.10%
Jan 2017
-2.01%
IPO
0.09%
Name

ConvaTec Group PLC

Chart & Performance

D1W1MN
XLON:CTEC chart
P/E
32.83
P/S
2.73
EPS
0.09
Div Yield, %
1.69%
Shrs. gr., 5y
0.80%
Rev. gr., 5y
4.61%
Revenues
2.29b
+6.85%
1,700,700,0001,733,900,0001,650,400,0001,688,300,0001,764,600,0001,832,100,0001,827,200,0001,894,300,0002,038,300,0002,072,500,0002,142,400,0002,289,200,000
Net income
191m
+46.20%
-173,700,000-286,500,000-93,400,000-202,800,000158,400,000221,600,0009,800,000112,500,000117,600,00062,900,000130,300,000190,500,000
CFO
396m
+7.84%
229,100,000147,300,000100,300,00074,900,000306,600,000352,000,000401,800,000399,500,000305,900,000281,700,000367,400,000396,200,000
Dividend
Aug 22, 20241.0763 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
IPO date
Oct 26, 2016
Employees
10,000
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT